ArriVent BioPharma Inc. (AVBP)
NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AVBP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $544.13M
- EPS (TTM)
- -$3.60
- Dividend yield
- None
- 52-week range
- 10.33 – 35.83
- Day range
- 10.38 – 11.35
- Volume / Avg
- 1.05M / 1.37M
- Beta
- —
- Shares outstanding
- 51.72M
52-week range
AVBP stock today
On Nov 20, AVBP ended the session at $10.52, shedding $0.74 (6.57%), versus the S&P 500's 3.70% decline. Shares are 70.6% below their 52-week high of $35.83, set on Jun 26, 2026 and 1.8% above the 52-week low of $10.33, near the bottom of the past year's range. AVBP is down 47.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 48.3%.
ArriVent BioPharma has posted a net loss over the last twelve months (EPS of -$3.60), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ArriVent BioPharma
Company profileArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Zhengbin Yao Ph.D.
- Headquarters
- Newtown Square, PA
- Employees
- 77
- IPO year
- 2024
- Website
- arrivent.com
Financial highlights
Full financialsArriVent BioPharma reported a net loss of $166.3 million, compared with a loss of $80.5 million a year earlier. Diluted earnings per share came in at -$4.32.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-166.31M | $-80.49M | $-69.33M |
| EPS (diluted) | $-4.32 | $-2.56 | $-32.38 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$26.20+149.05%
- Strong buy 0
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.81 vs $-1.04
- Surprise
- +22.12%
AVBP news
All AVBP news- ArriVent BioPharma GAAP EPS of -$0.81Seeking Alpha
- ArriVent BioPharma Announces Retirement of R&D President, Appointment of Priti Patel to Lead R&D, and Third Quarter 2026 Financial ResultsNasdaq
- ArriVent BioPharma Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- ArriVent BioPharma Consensus Price Target Increased 14.29% to $25.96NasdaqAVBP, BF.A
- ArriVent BioPharma, Inc. Announces Initial Phase 1 Data for CDH17-Targeted ADC ARR-217Nasdaq
- ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026GlobeNewswire
- ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026GlobeNewswire
- ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung CancerGlobeNewswire
ArriVent BioPharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs AVBP |
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs AVBP |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs AVBP |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs AVBP |
| BCAXBicara Therapeutics Inc. | 8.44 | -7.46% | $560.31M | vs AVBP |
| GERNGeron Corporation | 0.8707 | -4.63% | $560.94M | vs AVBP |
| ZVRAZevra Therapeutics Inc. | 8.76 | -3.42% | $521.26M | vs AVBP |
| ALMSAlumis Inc. | 3.96 | -8.54% | $514.09M | vs AVBP |
Indexes, lists and sector
ArriVent BioPharma stock FAQ
What is ArriVent BioPharma's stock price today?
AVBP last traded at $10.52 as of Nov 20, 4:00 PM EST, down 6.57% on the day. Prices are delayed at least 15 minutes.
Who is ArriVent BioPharma's CEO?
Dr. Zhengbin Yao Ph.D. is the chief executive officer of ArriVent BioPharma Inc., which has about 77 employees.
What is the AVBP 52-week high?
The 52-week high for AVBP is $35.83 and the 52-week low is $10.33. The stock is currently 70.6% below its high.